GLP-1 Medication During Menopause: What It Is and When It's Useful

GLP-1 medication, such as semaglutide and tirzepatide, is getting increasing attention for weight gain during menopause. It's prescription medication for a medical indication; not a means to lose a few kilos without a doctor's assessment. In this article you'll read what GLP-1 medication does, which side effects can occur, and when a doctor can assess whether it's a suitable addition.

In short

• GLP-1 medication affects, among other things, satiety, gastric emptying, and blood sugar regulation.
• In adults with obesity or overweight with a weight-related condition, tirzepatide in an EMA-assessed study, alongside diet and exercise, led to an average of at least 15% weight loss after 72 weeks. In the placebo group that was 3%.
• In a small retrospective study in postmenopausal women, weight loss with semaglutide after twelve months was higher in hormone therapy users than in non-users: an average of 16% versus 12%. This shows an association, not a cause-and-effect relationship.
• During menopause, weight loss requires extra attention to adequate protein, strength training, and medical monitoring, since muscle mass can already be declining with age and hormonal changes.

What is GLP-1 medication?

GLP-1 is a hormone your gut releases after a meal. GLP-1 receptor agonists mimic part of that action. They can strengthen the feeling of satiety, slow gastric emptying, and affect insulin release when blood glucose rises. Many medications are prescribed to be administered weekly with an injection pen.

The question what is GLP-1 medication is therefore not only about appetite. It's also about who the medication is registered for, what other conditions someone has, what medication they use, and whether the potential benefit outweighs the risks. A BIG-registered doctor assesses this on a per-person basis.

Weight gain during menopause: when does a medical assessment make sense?

Weight and body shape can change during peri- and postmenopause. Sleep, stress, exercise, muscle mass, nutrition, medication, and hormonal changes can all play a role. That makes a single explanation for weight gain during menopause unreliable.

A doctor can consider a broader assessment when your weight increases despite achievable lifestyle changes, there are signs of disrupted glucose regulation, or when being overweight coincides with other health risks. GLP-1 medication isn't the first or only step in that case. The European product information for tirzepatide describes use in adults with obesity, or with overweight plus at least one weight-related condition, always alongside diet and exercise.

Semaglutide and tirzepatide: what's the difference?

Semaglutide activates the GLP-1 receptor. Tirzepatide works on both the GLP-1 and the GIP receptor. Both medications have different registered uses, dosages, and contraindications. The brand name alone is therefore not a basis for a choice.

For the question tirzepatide versus semaglutide, it's important to keep two things separate. Research on average weight change shows differences between medications, but an average result doesn't predict what one person experiences. In addition, the medical indication can differ: medications and doses used for diabetes aren't automatically the same as those for weight management.

A large summary of randomized research reported in adults without diabetes an average of about 14.9% weight loss with semaglutide 2.4 mg after 68 weeks and 20.9% with tirzepatide 15 mg after 72 weeks. These figures come from study groups with specific eligibility criteria; they aren't a personal treatment outcome.

Figures in context

1. 72 weeks: in an EMA-assessed study, participants using tirzepatide lost an average of at least 15% of their weight, versus 3% with placebo, depending on the dose.
2. More than 85%: in that same study, more than 85% of participants using tirzepatide lost at least 5% of their starting weight; with placebo that was 35%.
3. 16% versus 12%: a retrospective cohort study among 106 postmenopausal women found a higher average weight loss with semaglutide after twelve months in women using hormone therapy. The hormone therapy group in the study included 16 women; the finding therefore needs confirmation in randomized research.

GLP-1 medication and hormone therapy during menopause

Hormone therapy and GLP-1 medication have different goals. Hormone therapy can be considered for menopause symptoms after an individual benefit-risk assessment. GLP-1 medication can be considered for weight management with a suitable indication. The medications aren't interchangeable, and hormone therapy isn't a standard treatment for weight loss.

The small study in postmenopausal women using semaglutide shows an association between hormone therapy and more weight loss. Because it's retrospective research, other differences between the groups could partly explain the outcome. So don't see this as proof that the combination works better for everyone, but as a reason to discuss the combination carefully with a doctor.

The search question hormone therapy menopause weight gain deserves the same nuance: weight gain has multiple causes, and a treatment plan starts with establishing which factors weigh most heavily in your situation.

Side effects of semaglutide and tirzepatide

The most commonly reported semaglutide side effects and side effects of tirzepatide are gastrointestinal symptoms, such as nausea, diarrhea, constipation, vomiting, or abdominal pain. These symptoms often occur while building up the dose. The product information also lists more serious, less common risks and situations where a medication may not be suitable.

Always tell your doctor about other medication, previous pancreatitis, gallbladder problems, kidney problems, pregnancy, or a wish to conceive. Because GLP-1 medication can slow gastric emptying, a doctor can also assess whether the timing or absorption of oral medication needs attention. Don't stop or start prescribed medication on your own.

Muscle mass, nutrition, and exercise

Weight loss isn't automatically only fat loss. That's why preserving muscle mass is an important talking point, especially during menopause. A doctor or dietitian can tailor protein needs, strength training, and monitoring to your starting situation, medical history, and any symptoms.

General advice such as 1.2 to 1.6 grams of protein per kilogram of body weight and two to three strength sessions a week can be appropriate for some people, but isn't a universal prescription. With kidney disease, being underweight, eating problems, or intensive sport, this calls for personal tailoring.

How Menovia assesses the choice

At Menovia, GLP-1 medication, when medically appropriate, is an optional addition within a treatment plan and not a standalone product. BIG-registered doctors assess your symptoms, medical history, and test results. The seven-step program can draw on four diagnostic pillars: blood testing, DNA testing, microbiome analysis, and the DUTCH test.

Menovia offers three programs at €75, €135, and €199. Since May 2026, partial reimbursement is possible; compounded medication, DHEA, and testosterone aren't covered by this. Which diagnostics, hormone therapy, or additional GLP-1 medication is appropriate is always determined individually.

Frequently asked questions

What is GLP-1 medication and how does it work?

GLP-1 medication mimics a gut hormone. It can strengthen satiety, slow gastric emptying, and affect blood sugar regulation. It's prescription medication and is only prescribed after a medical assessment.

Is semaglutide better than tirzepatide during menopause?

Not by definition. Tirzepatide and semaglutide work differently and have different registered uses. The choice depends on your medical indication, history, other medication, possible side effects, and treatment goal.

Can I combine GLP-1 medication with hormone therapy?

A doctor can assess that in some situations. A small retrospective study in postmenopausal women saw an association between hormone therapy and more weight loss with semaglutide, but this isn't yet proof that the combination is better or safer for everyone.

What side effects can semaglutide cause?

Gastrointestinal symptoms, such as nausea, diarrhea, constipation, vomiting, and abdominal pain, are common. Always discuss previous gallbladder, pancreas, or kidney problems and all other medication with your doctor.

Is GLP-1 medication intended only for weight gain during menopause?

No. Menopause on its own isn't an indication. A doctor assesses, among other things, weight, possible weight-related conditions, lifestyle, medication, and health risks.

How much weight will I lose with GLP-1 medication?

That can't be reliably predicted in advance. Study averages apply to selected groups and dosages. Your result depends, among other things, on the indication, the medication, the dose, side effects, lifestyle, and how long the treatment is followed.

In conclusion

GLP-1 medication can be an additional option for some women with menopause symptoms and a suitable medical indication. It's not a replacement for lifestyle, medical guidance, or a careful conversation about hormone therapy. A plan that also looks at muscle mass, nutrition, symptoms, and other medication matters more than just the number on the scale.

Sources

• European Medicines Agency (EMA): Mounjaro
• Research on semaglutide in postmenopausal women with and without hormone therapy
• Meta-analysis of GLP-1 receptor agonists and weight loss

Related articles

• GLP-1 and Menovia: how we use it in your program
• How long menopause typically lasts
• More about Menovia's programs

This information is intended as an educational resource and does not replace medical advice, diagnosis, or treatment. If you have symptoms or questions about your personal situation, we recommend consulting a doctor.